Valeo Pharma Statistics
Total Valuation
Valeo Pharma has a market cap or net worth of 4.63 million. The enterprise value is 49.22 million.
| Market Cap | 4.63M |
| Enterprise Value | 49.22M |
Important Dates
The last earnings date was Wednesday, January 29, 2025.
| Earnings Date | Jan 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Valeo Pharma has 98.68 million shares outstanding. The number of shares has increased by 5.43% in one year.
| Current Share Class | 98.68M |
| Shares Outstanding | 98.68M |
| Shares Change (YoY) | +5.43% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 22.55% |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| PB Ratio | -0.10 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.12 |
| EV / Sales | 1.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.91 |
Financial Position
The company has a current ratio of 0.27
| Current Ratio | 0.27 |
| Quick Ratio | 0.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -17.59 |
| Interest Coverage | -1.05 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.07% |
| Return on Invested Capital (ROIC) | -55.16% |
| Return on Capital Employed (ROCE) | 42.98% |
| Revenue Per Employee | 552,025 |
| Profits Per Employee | -332,185 |
| Employee Count | 110 |
| Asset Turnover | 1.37 |
| Inventory Turnover | 4.22 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.18% in the last 52 weeks. The beta is 1.05, so Valeo Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -70.18% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 0.27 |
| Relative Strength Index (RSI) | 42.68 |
| Average Volume (20 Days) | 6,836 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Valeo Pharma had revenue of 38.64 million and -23.25 million in losses. Loss per share was -0.26.
| Revenue | 38.64M |
| Gross Profit | 8.70M |
| Operating Income | -11.74M |
| Pretax Income | -23.25M |
| Net Income | -23.25M |
| EBITDA | -10.21M |
| EBIT | -11.74M |
| Loss Per Share | -0.26 |
Balance Sheet
The company has 5.16 million in cash and 51.20 million in debt, giving a net cash position of -46.04 million or -0.47 per share.
| Cash & Cash Equivalents | 5.16M |
| Total Debt | 51.20M |
| Net Cash | -46.04M |
| Net Cash Per Share | -0.47 |
| Equity (Book Value) | -45.63M |
| Book Value Per Share | -0.46 |
| Working Capital | -36.82M |
Cash Flow
In the last 12 months, operating cash flow was -2.83 million and capital expenditures -86,149, giving a free cash flow of -2.91 million.
| Operating Cash Flow | -2.83M |
| Capital Expenditures | -86,149 |
| Free Cash Flow | -2.91M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 22.51%, with operating and profit margins of -30.37% and -60.18%.
| Gross Margin | 22.51% |
| Operating Margin | -30.37% |
| Pretax Margin | -60.18% |
| Profit Margin | -60.18% |
| EBITDA Margin | -26.41% |
| EBIT Margin | -30.37% |
| FCF Margin | n/a |
Dividends & Yields
Valeo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.43% |
| Shareholder Yield | n/a |
| Earnings Yield | -502.45% |
| FCF Yield | -62.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Valeo Pharma has an Altman Z-Score of -6.35. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.35 |
| Piotroski F-Score | n/a |